Get the Daily Brief
Latest Biotech News
Gilead front-loads $1.675B for Ouro... reshapes Galapagos role
Gilead Sciences agreed to acquire Ouro Medicines in a deal that pays roughly $1.675 billion upfront and up to $500 million in milestones, adding OM336 (gamgertamig), a BCMAxCD3 T‑cell engager, to...
Novartis buys Synnovation’s PI3Kα program — $2B upfront
Novartis agreed to acquire Pikavation Therapeutics, Synnovation’s subsidiary, for up to $3 billion including $2 billion upfront to secure SNV4818, a pan‑mutant selective PI3Kα inhibitor in early...
Pfizer, Valneva miss statistical bar on Lyme shot — plan to file anyway
Pfizer and Valneva reported Phase 3 data showing their Lyme disease vaccine reduced cases by roughly 70–73% but failed to meet the trial’s pre‑specified statistical threshold because fewer than...
Apogee posts long‑acting eczema wins — dosing every 3–6 months shows durability
Apogee Therapeutics released Phase 2 maintenance data for zumilokibart (APG‑777) showing durable skin and itch responses with dosing intervals of three and six months. Company‑reported endpoints...
Sanofi pays $180M up front for Kali’s trispecific — big autoimmune bet
Sanofi licensed KT‑501, a trispecific T‑cell engager from Kali Therapeutics, in a deal that includes roughly $180 million in upfront and near‑term payments and more than $1 billion in milestones...
RyboDyn raises $10M to mine the dark proteome for cancer targets
RyboDyn closed a $10 million seed round to accelerate RyboCypher, its platform for discovering oncology targets in the 'dark proteome'—proteins encoded by non‑canonical RNAs and cryptic peptides....
Crossbow closes $77M Series B to advance T‑Bolt T‑cell engagers
Crossbow Therapeutics raised $77 million in Series B financing to advance CBX‑250, a first‑in‑class T‑cell engager targeting relapsed or refractory myeloid malignancies, and to nominate a second...
FDA clears IND for ENDO‑205 — first‑in‑class nonhormonal endometriosis peptide
Endocyclic Therapeutics secured IND clearance from the FDA for ENDO‑205, a targeted, nonhormonal peptide therapeutic for endometriosis. The company positions ENDO‑205 as a first‑in‑class approach...
AroLNPs redirect mRNA vaccines to lymph nodes — liver detargeting breakthrough
Researchers at the University of Pennsylvania reported a redesign of ionizable lipids that produced aromatic, bioreducible LNPs (aroLNPs) which reduce liver accumulation and enhance delivery to...
WHO urges rollout of near point‑of‑care TB molecular tests — new guidance
On World Tuberculosis Day the WHO issued guidance endorsing near point‑of‑care (nPOC) nucleic acid amplification tests (NAATs) as initial diagnostics for pulmonary TB in adults and adolescents,...
Gilead’s $1.68B bet: Ouro buyout reshapes Galapagos role
Gilead agreed to acquire Ouro Medicines in a front‑loaded deal that pays roughly $1.675–1.68 billion upfront for OM336, a BCMAxCD3 T‑cell engager being developed for autoimmune disorders. Company...
Novartis spends big on PI3Kα: Pikavation deal expands breast‑cancer pipeline
Novartis moved to acquire Pikavation Therapeutics (a Synnovation subsidiary) in a deal valuing the transaction at up to $3 billion, including a $2 billion upfront component for a mutant‑selective...
Pfizer, Valneva press regulators... Lyme vaccine hits statistical snag
Pfizer and Valneva reported Phase III Valor results showing the Lyme disease vaccine reduced cases by roughly 70–73% but missed the trial’s prespecified statistical threshold because fewer than...
Apogee’s long‑interval eczema win: durability with quarterly to semiannual dosing
Apogee Therapeutics released mid‑stage maintenance data showing its anti‑IL‑13 antibody zumilokibart maintained clinical benefit with less frequent dosing. In the Phase II maintenance readout, 75%...
Sanofi returns to T‑cell engagers: $1.2B pact for Kali’s trispecific
Sanofi struck a global license and collaboration for Kali Therapeutics’ trispecific T‑cell engager KT‑501, providing approximately $180 million in upfront and near‑term payments with more than $1...
Engineered LNPs steer mRNA to lymph nodes — liver detargeting demonstrated
Researchers at the University of Pennsylvania reported a redesigned class of lipid nanoparticles (aroLNPs) that markedly reduce liver delivery and instead concentrate mRNA in lymph nodes, boosting...
Rapid diagnostics surge: Roche’s CE mark and Diasorin’s US bet
Roche secured CE marking for its Cobas Eplex respiratory pathogen panel 3 (RP3), a multiplex molecular assay that detects up to 25 viral and bacterial respiratory targets and offers flexible...
Washington hears biotech on China: investors and experts press urgency
A delegation of biotech investors met with a congressional commission charged with safeguarding U.S. biotech competitiveness, urging policies that respond to China’s rapid gains in clinical trials...
DNA and IVD capacity builds: Artis opens synthetic DNA hub; IDT moves into clinical assays
Artis BioSolutions launched a synthetic DNA manufacturing hub in Boston using Syngoi Technologies’ enzymatic platform to shorten supply chains and support its Watertown GMP site; the company...
Immunotherapy financings: Crossbow $77M, Immutrin $86M to advance candidates
Two financings underscored capital flow into next‑generation immunotherapies. Crossbow Therapeutics closed a $77 million Series B to advance its T‑Bolt platform and first‑in‑human candidate...